TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17033111
Drug: Amoxicillin with
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin with clarithromycin and proton pump inhibitor (PPI)
Study: 17033111
Drug: Amoxicillin with
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin with clarithromycin and PPI supplemented with Lacidofil
Study: 10608746
Drug: pleconaril 200
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pleconaril 200 mg twice daily (initial dose of 400 mg)
Study: 8859234
Drug: 4-mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg intravenous ondansetron
Study: 7959523
Drug: Paroxetine (1x20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (1x20 mg/day)
Study: 7959523
Drug: Doxepin (2x50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (2x50 mg/day)
Study: 3298420
Drug: Moclobemide (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (selective MAO-A-inhibitor)
Study: 24082728
Drug: OHA +
Normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHA + 50 mg elemental zinc as zinc sulphate supplementation for 12 weeks
Study: 17164695
Drug: Single-dose activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose activated charcoal (SDAC)
Study: 17164695
Drug: Multiple-dose activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose activated charcoal (MDAC)
Study: 10922195
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (2% lidocaine, minimum of 5 doses, approximately 40 microL per dose)
Study: 10922195
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (3.5-5.5 mL of a combination of 0.75% bupivacaine hydrochloride, 2% lidocaine, and hyaluronidase)
Study: 8786727
Drug: GHRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1 microgram/kg body weight intravenous bolus)
Study: 8786727
Drug: L-arginine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (50 g in 50 mL normal saline over 30 minutes)
Study: 2199394
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose polyoestradiol phosphate (160 mg i.m. monthly)
Study: 30929591
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise treatment group (n = 21)
Study: 24642450
Drug: Weekly estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly estimated intake of isoflavones
Study: 19520448
Drug: 8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Gy single-dose RT
Study: 16616994
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) doses of 12 mg and 24 mg IM
Study: 16616994
Drug: Pre-session supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-session supplements of HYD (12 mg or 24 mg)
Study: 16616994
Drug: Different FR/unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different FR/unit dose combinations
Study: 11323364
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg epidural S(+)‐ketamine
Study: 11323364
Drug: Ropivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (10 mg/mL, 10‐20 mL)
Study: 28343225
Drug: Vadadustat (240,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat (240, 370, 500, or 630 mg once-daily for 6 weeks)
Study: 26304864
Drug: Deferoxamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine infusion
Study: 8706772
Drug: Buffered sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered sublingual captopril (12.5 mg)
Study: 8706772
Drug: Peroral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral captopril (administered with 100 ml of water)
Study: 6143667
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg b.i.d.
Study: 29217088
Drug: Induction cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cisplatin (80 mg/m2) and docetaxel (75 mg/m2) for 3 cycles followed by surgery and adjuvant erlotinib for 12 months
Study: 26763489
Drug: Ivabradine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 2.5 mg BID
Study: 26763489
Drug: Ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 5 mg BID
Study: 15205987
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac daily
Study: 15205987
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg diclofenac daily
Study: 11449205
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 400 microg once daily
Study: 11449205
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 200 microg once daily
Study: 11449205
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 100 microg once daily
Study: 10984368
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 200 microg once daily
Study: 11449205
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 84 microg twice daily
Study: 11449205
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate or BUD
Study: 2890805
Drug: Vi capsular
Normalized name: typhoid vaccine VI capsular polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi capsular polysaccharide (CPS) vaccine (25 micrograms, single intramuscular injection)
Study: 17899018
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg morphine
Study: 23614336
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without telemetric monitoring (Control Group)
Study: 3330992
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30-60 mg/day)
Study: 3330992
Drug: Hydrochlorothiazide (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25-50 mg/day)
Study: 29381560
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (3-g pill daily for 12 weeks, containing 1.8-g eicosapentaenoic acid and 1.2-mg docosapentaenoic acid)
Study: 29381560
Drug: Placebo (44.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (44.8 mg of high oleic safflower oil)
Study: 27317632
Drug: α1‐adrenergic blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1‐adrenergic blockade (oral Prazosin, 0.05 mg/kg)
Study: 26215644
Drug: Early, individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, individually tailored occupational rehabilitation intervention using acceptance and commitment therapy dialogue and individual-placement-and-support-inspired tools.
Study: 24124710
Drug: Mannitol dosage
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol dosage in Groups A, B, C
Study: 18339160
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA) using propofol and remifentanil
Study: 9579448
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 microg/day
Study: 15641867
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 to 80 mg b.i.d.
Study: 15641867
Drug: Risperidone 3
Normalized name: risperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 3 to 5 mg b.i.d.
Study: 11384791
Drug: Benzodiazepines administered
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines administered by paramedics
Study: 9788422
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (no prophylactic therapy)
Study: 29769507
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Study: 29769507
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Study: 29769507
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2μg/kg)
Study: 10709884
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 13 g l(‐1) of protein
Study: 10709884
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 15 g l(‐1) of protein
Study: 10709884
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 18/20 g l(‐1) of protein
Study: 8684510
Drug: Physostigmine capsules
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine capsules (up to 10 mg per day)
Study: 8684510
Drug: Physostigmine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine patch (transdermal application)
Study: 1627368
Drug: 75 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1)
Study: 1627368
Drug: 25 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2 weekly for 12 courses (arm 2)
Study: 22895810
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (500 mg/day)
Study: 22895810
Drug: L-carnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (500 mg/day)
Study: 22895810
Drug: Mg-L-carnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-L-carnitine (500 mg/day magnesium and 500 mg/day L-carnitine)
Study: 19800827
Drug: Calculated based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated based on fixed absorbed dose of 400 Gy in GR3
Study: 19800827
Drug: Calculated based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated based on fixed absorbed dose of 100 Gy in GR1
Study: 19800827
Drug: Average activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average activity administered to GR2
Study: 19800827
Drug: Average activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average activity administered to GR3
Study: 19800827
Drug: Thyroid absorbed
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid absorbed dose in GR2
Study: 19800827
Drug: Thyroid absorbed
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid absorbed dose in GR3
Study: 18077922
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica
Study: 18077922
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream (vehicle)
Study: 18077922
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica (in cold and dry conditions)
Study: 12399266
Drug: Betaine supplementation
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine supplementation (6 g/d)
Study: 7755536
Drug: Eight-session telephone
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight-session telephone behavior therapy program
Study: 7755536
Drug: Telephone behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone behavior therapy
Study: 6270809
Drug: Nicergoline (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (2.5 mg i.v.)
Study: 24157401
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) and vasopressin (AVP)
Study: 16011816
Drug: Vardenafil 5
Normalized name: vardenafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 5 mg, 10 mg, or 20 mg
Study: 9860409
Drug: Oral norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral norfloxacin 400 mg/12 h for 7 days
Study: 9860409
Drug: Norfloxacin plus
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin plus intravenous ceftriaxone 2 g daily during the first 3 days of admission
Study: 9860409
Drug: Norfloxacin plus
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin plus intravenous ceftriaxone
Study: 2762182
Drug: APF foam
Normalized name: SODIUM FLUORIDE 1.5498 g in 126 g ORAL AEROSOL, FOAM [Ionite APF Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF foam (0.9 g)
Study: 2762182
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel (4 g)
Study: 1155873
Drug: Continuous agar
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous agar oral administration, 125 mg before each of the seven formula feedings
Study: 1155873
Drug: Discontinuous agar
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous agar administration, 250 mg before three of the seven formula feedings
Study: 28458115
Drug: Pregnenolone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone treatment (n=6)
Study: 28458115
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=5)
Study: 20948432
Drug: Olanzapine LAI
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine LAI 300 mg/2 weeks
Study: 20948432
Drug: Olanzapine LAI
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine LAI 150 mg/2 weeks
Study: 20948432
Drug: Olanzapine LAI
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine LAI 405 mg/4 weeks
Study: 17315804
Drug: Oral-health workshop
Normalized name: Healthy Mama Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-health workshop
Study: 11822223
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g once daily (single dose)
Study: 9762946
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (2 g amino acid/M2/dose twice daily)
Study: 28419204
Drug: Sabin‐IPV high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabin‐IPV high dose
Study: 28419204
Drug: Sabin‐IPV medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabin‐IPV medium dose
Study: 28419204
Drug: Sabin‐IPV low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabin‐IPV low dose
Study: 28419204
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine
Study: 25923490
Drug: Haloperidol (low-dose)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (low-dose)
Study: 22236169
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide (CH) intracanal medication for 14 days
Study: 22133165
Drug: Non-pharmacological multicomponent
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological multicomponent group therapy (MAKS) - motor stimulation, practice in activities of daily living, cognitive stimulation, conducted in groups of ten patients for 2 hours, 6 days a week for 12 months.
Study: 19758253
Drug: Water solutions
Normalized name: water Irrigation Solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water solutions containing 1.5% SLS
Study: 15249273
Drug: Donepezil (high-dose)
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil (high-dose)
Study: 30326124
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (200 mg once or twice per day)
Study: 15219522
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 1000 mg
Study: 15219522
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 1500 mg
Study: 15219522
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 2000 mg
Study: 15219522
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 3000 mg
Study: 11285986
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration with oocyte collection intervals of 33-41 hours
Study: 26950065
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration
Study: 9676345
Drug: Theophylline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (500 mg b.i.d.)
Study: 3209607
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (CTX) - 4 doses for 2 days
Study: 3209607
Drug: Benzylpenicillin combined
Normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzylpenicillin combined with cloxacillin (BPC) - 6 doses for 3 days
Study: 3209607
Drug: Cefotaxime with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime with additional antibiotics for fever (CTX-ADD)
Study: 3209607
Drug: Benzylpenicillin combined
Normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzylpenicillin combined with cloxacillin with additional antibiotics for fever (BPC-ADD)
Study: 30642737
Drug: Probiotic plus
Normalized name: CVS Advanced Probiotic Plus Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic plus selenium (200 μg/day selenium + 2 × 10^9 CFU/day of Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum)
Study: 28315596
Drug: Strengthening exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthening exercises for hip and trunk muscles (three weekly sessions for eight weeks)
Study: 25562195
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate tea (5 g/day) for 6 weeks
Study: 25562195
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g/day) for 6 weeks
Study: 21999374
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cells (ASC) injection
Study: 21999374
Drug: Traditional compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional compression sleeve therapy (CST)
Study: 17130417
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group from the clinical phase III US Insulin‐like Growth Factor‐I Trial
Study: 9269013
Drug: Hydroxyapatite-coated titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite-coated titanium plasma-sprayed implants
Study: 9269013
Drug: Titanium plasma-sprayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium plasma-sprayed implants
Study: 24046411
Drug: 20 nmol
Normalized name: QUINAPRIL HYDROCHLORIDE 20 nmol / HYDROCHLOROTHIAZIDE 12.5 mg ORAL TABLET, FILM COATED [Quinapril Hydrochloride and Hydrochlorothiazide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 nmol of c-di-GMP administered intramuscularly (IM) in conjunction with penicillin G for 5 days
Study: 24046411
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with saline and penicillin G
Study: 24046411
Drug: Gavage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gavage treatment with 20 nmol of c-di-GMP in conjunction with penicillin G
Study: 24046411
Drug: IM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM treatment with c-di-GMP
Study: 19674132
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus bismuth subcitrate (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., bismuth subcitrate 300 mg q.i.d. for 14 days)
Study: 19674132
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus bismuth subcitrate and vitamins C (500 mg b.i.d.) and E (200 IU b.i.d. for 30 days)
Study: 17175645
Drug: Shengmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai injection (40 ml) with 250 ml 50 g/L glucose solution for 3 days, 1 time per day
Study: 17175645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 290 ml 50 g/L glucose injection liquid for 3 days, 1 time per day
Study: 11353932
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (10 ng/kg/min for 1 hour)